Jim Miller

Is the contract-only CMO an endangered species?

Measuring the size of the market for contract manufacturing services requires a careful hand.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Service providers must focus on delivering a superior customer experience.

The evolving bio/pharmaceutical business model poses risk for CMOs.

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

Addressing supply-chain challenges.